Koru Medical Systems Inc Expected To Post A Loss Of 4 Cents A Share: Earnings Preview

Koru Medical Systems

12/11/2024 03:47

* KORU Medical Systems Inc  KRMD.OQ   KRMD.O  is expected
to show
a rise in quarterly revenue when it reports  results on November
13 for the period ending September 30 2024
    * The Mahwah New Jersey-based  company is expected to report
a
9.7% increase in revenue to $7.68 million from $7 million a year
ago, according to the mean estimate from 5 analysts, based on
LSEG data.
    * ​LSEG's mean analyst estimate for KORU Medical Systems Inc
is
for a loss of 4 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for KORU
Medical
Systems Inc is $4.00​, above​ its last closing price of $2.89.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.05       -0.04      -0.02     Beat    52.4
 Mar. 31 2024  -0.04       -0.04      -0.02     Beat    47.4
 Dec. 31 2023  -0.05       -0.04      -0.03     Beat    25​
 Sep. 30 2023  -0.06       -0.05      -0.03     Beat    40
 ​​Jun.        -0.06       -0.06      -0.05     Beat    11.8
 30 2023                                                
 Mar. 31 2023  -0.04       -0.05      -0.05     Met     0​
 Dec. 31 2022  -0.06       -0.06      -0.04     Beat    29.4
 Jan. 1 0001   -0.05       -0.05      -0.03     Beat    43.7
 This summary was machine generated November 12 at 03:47 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)